SCHEMBL25819451

SCHEMBL25819451

CC1(CN2CCC3(CC2)CC(NC(=O)OCc2ccccc2)C3)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.43
ATXN2 Q99700 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.42
MAPK1 P28482 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
NTSR1 P30989 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
DPP4 P27487 1/20 0.41
KCNH2 Q12809 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
STS P08842 1/20 0.40
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSK P43235 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29179859 0.92 ENPP2 (0.48) ENPP2ATXN2L3MBTL1MAPTMAPK1
SCHEMBL25935336 0.91 ENPP2 (0.44) ENPP2ATXN2L3MBTL1MAPTMAPK1
SCHEMBL30135999 0.86 ENPP2 (0.44) ENPP2ATXN2L3MBTL1MAPK1MEN1
SCHEMBL30135872 0.86 YAP1 (0.47) ENPP2ATXN2L3MBTL1MAPTMAPK1
SCHEMBL30965581 0.85 DRD2 (0.47) ENPP2ATXN2L3MBTL1MAPTMAPK1
SCHEMBL8328356 0.84 ENPP2 (0.52) ENPP2ATXN2L3MBTL1NPSR1MEN1
SCHEMBL25819450 0.83 ENPP2 (0.47) ENPP2ATXN2MEN1KMT2ADPP4
SCHEMBL30121231 0.83 L3MBTL1 (0.51) L3MBTL1MAPTMAPK1NPSR1NTSR1
SCHEMBL25935391 0.82 L3MBTL1 (0.49) L3MBTL1MAPTMAPK1NPSR1NTSR1
SCHEMBL25309145 0.82 MEN1 (0.47) MAPTNPSR1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116322700-B Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2024-08-20 CN disclosed
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ENPP2 1565/4885ATXN2 2262/4885L3MBTL1 964/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 ENPP2 2034/4885ATXN2 1927/4885L3MBTL1 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.